Literature DB >> 7688548

Hormone resistant prostatic adenocarcinoma. An evaluation of prognostic factors in pre- and post-treatment specimens.

A Berner1, J M Nesland, H Waehre, J Silde, S D Fosså.   

Abstract

Pre- and post-treatment specimens from 47 patients with hormone resistant prostatic carcinoma were compared with each other regarding histological grade and immunoreactivity for p53 protein, neuron specific enolase and c-erbB-2 protein. Significantly more specimens expressed a high malignancy grade when the tumour had become hormone resistant than at the time of initial diagnosis (Gleason P: < 0.0001, WHO P:0.0003). p53 protein immunoreactivity increased significantly with disease progression (P:0.006), while tissue PSA immunoreactivity was reduced in post-treatment specimens (P:0.011). p53 protein expression did not correlate with histological grade or PSA expression and seems to be an independent parameter which participates late in the neoplastic transformation. Thirty-two percent of the tumours were neuron specific enolase positive, but this parameter did not correlate with development of hormone resistance. c-erbB-2 protein reactivity was not recognised.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7688548      PMCID: PMC1968568          DOI: 10.1038/bjc.1993.344

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  44 in total

1.  Long-term follow-up after radical prostatectomy. Identification of prognostic variables.

Authors:  J A Smith; A D Hernandez; C J Wittwer; J M Avent; J Greenwood; E H Hammond; R G Middleton
Journal:  Urol Clin North Am       Date:  1991-08       Impact factor: 2.241

2.  Neuro-endocrine cells--a new prognostic parameter in prostate cancer.

Authors:  R J Cohen; G Glezerson; Z Haffejee
Journal:  Br J Urol       Date:  1991-09

Review 3.  The p53 tumour suppressor gene.

Authors:  A J Levine; J Momand; C A Finlay
Journal:  Nature       Date:  1991-06-06       Impact factor: 49.962

4.  Tissue concentrations of prostate-specific antigen in prostatic carcinoma and benign prostatic hyperplasia.

Authors:  T G Pretlow; T P Pretlow; B Yang; C S Kaetzel; C M Delmoro; S M Kamis; D R Bodner; E Kursh; M I Resnick; E L Bradley
Journal:  Int J Cancer       Date:  1991-11-11       Impact factor: 7.396

5.  p53, c-erbB-2 and the epidermal growth factor receptor in the benign and malignant prostate.

Authors:  K Mellon; S Thompson; R G Charlton; C Marsh; M Robinson; D P Lane; A L Harris; C H Horne; D E Neal
Journal:  J Urol       Date:  1992-02       Impact factor: 7.450

6.  Alterations of the P53 gene are associated with the progression of a human prostate carcinoma.

Authors:  P J Effert; A Neubauer; P J Walther; E T Liu
Journal:  J Urol       Date:  1992-03       Impact factor: 7.450

7.  Wild-type p53 suppresses growth of human prostate cancer cells containing mutant p53 alleles.

Authors:  W B Isaacs; B S Carter; C M Ewing
Journal:  Cancer Res       Date:  1991-09-01       Impact factor: 12.701

8.  Widespread p53 overexpression in human malignant tumors. An immunohistochemical study using methacarn-fixed, embedded tissue.

Authors:  P L Porter; A M Gown; S G Kramp; M D Coltrera
Journal:  Am J Pathol       Date:  1992-01       Impact factor: 4.307

9.  The relationship between c-erbB-2 expression, S-phase fraction and prognosis in breast cancer.

Authors:  S M O'Reilly; D M Barnes; R S Camplejohn; J Bartkova; W M Gregory; M A Richards
Journal:  Br J Cancer       Date:  1991-03       Impact factor: 7.640

10.  c-erbB-2 protein overexpression in breast cancer is a risk factor in patients with involved and uninvolved lymph nodes.

Authors:  W J Gullick; S B Love; C Wright; D M Barnes; B Gusterson; A L Harris; D G Altman
Journal:  Br J Cancer       Date:  1991-03       Impact factor: 7.640

View more
  7 in total

1.  Development of a microplate assay for serum chromogranin A (CgA): establishment of normal reference values and detection of elevated CgA in malignant diseases.

Authors:  T L Wu; C P Chang; K C Tsao; C F Sun; J T Wu
Journal:  J Clin Lab Anal       Date:  1999       Impact factor: 2.352

2.  The effect of androgen deprivation on malignant and benign prostate tissue.

Authors:  P Guinan; D Didomenico; J Brown; M Shaw; R Sharifi; V Ray; S Shott; M Rubenstein
Journal:  Med Oncol       Date:  1997 Sep-Dec       Impact factor: 3.064

3.  A rare case of large cell neuroendocrine carcinoma.

Authors:  Diwei Lin; Amanda Jia Hui Tan; Agnelo Francis De Sousa; Rajinder Singh-Rai
Journal:  BMJ Case Rep       Date:  2014-10-19

4.  Cells in various benign and malignant conditions of the human prostate express different antigenic phenotypes.

Authors:  O I Turhan; N E Aydin; O Sariyüce; S Ozkan
Journal:  Int Urol Nephrol       Date:  1998       Impact factor: 2.370

5.  Co-expression and impact of prostate specific membrane antigen and prostate specific antigen in prostatic pathologies.

Authors:  Awatef Ben Jemaa; Yosra Bouraoui; Sataa Sallami; Ahmed Banasr; Nawfel Ben Rais; Latifa Ouertani; Yassin Nouira; Ali Horchani; Ridha Oueslati
Journal:  J Exp Clin Cancer Res       Date:  2010-12-28

6.  The expression and localisation of beta-nerve growth factor (beta-NGF) in benign and malignant human prostate tissue: relationship to neuroendocrine differentiation.

Authors:  A B Paul; E S Grant; F K Habib
Journal:  Br J Cancer       Date:  1996-12       Impact factor: 7.640

7.  Prostatic carcinoma: a multivariate analysis of prognostic factors.

Authors:  A Berner; S Harvei; S Tretli; S D Fosså; J M Nesland
Journal:  Br J Cancer       Date:  1994-05       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.